|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli leading to decreased caspase-3 activation.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 37 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II Phase I Preclinical Discovery and Unknown stages are 3 5 21 2 and 1 respectively. Similarly the universities portfolio in Preclinical stages comprises 5 molecules respectively. Report covers products from therapy areas Central Nervous System Metabolic Disorders Cardiovascular Gastrointestinal Infectious Disease and Ophthalmology which include indications Parkinson's Disease Alzheimer's Disease Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Neurodegenerative Diseases Lewy body Dementia Amyloidosis Constipation Familial Amyloid Neuropathies Glaucoma Human Immunodeficiency Virus (HIV) Infections (AIDS) Huntington Disease Schizophrenia Spinal Cord Injury Stroke Traumatic Brain Injury and Type 2 Diabetes.
The latest report Alpha Synuclein-Pipeline Review H2 2017 outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/alpha-synuclein-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881475/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
AC Immune SA
AFFiRiS AG
BioArctic AB
Biogen Inc
Evotec AG
Genmab A/S
H. Lundbeck A/S
ICB International Inc
MedImmune LLC
Neuropore Therapies Inc
nLife Therapeutics SL
Prothena Corp Plc
QR Pharma Inc
reMYND NV
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881475/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indication H2 2017
Number of Products under Development by Companies H2 2017
Number of Products under Development by Companies H2 2017 (Contd..1)
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Products under Development by Companies H2 2017 (Contd..2) H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Products under Investigation by Universities/Institutes H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Pipeline by AC Immune SA H2 2017
Pipeline by AFFiRiS AG H2 2017
Pipeline by BioArctic AB H2 2017
Pipeline by Biogen Inc H2 2017
Pipeline by Evotec AG H2 2017
Pipeline by Genmab A/S H2 2017
Pipeline by H. Lundbeck A/S H2 2017
Pipeline by ICB International Inc H2 2017
Pipeline by MedImmune LLC H2 2017
Pipeline by Neuropore Therapies Inc H2 2017
Pipeline by nLife Therapeutics SL H2 2017
Pipeline by Prothena Corp Plc H2 2017
Pipeline by QR Pharma Inc H2 2017
Pipeline by reMYND NV H2 2017
Dormant Products H2 2017
Dormant Products H2 2017 (Contd..1) H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881475/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
